Helus Pharma

Cybin Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel psychedelic-based therapeutics for various mental health conditions. Headquartered in Canada, the company's primary focus is on addressing unmet needs in areas such as depression, anxiety, and substance use disorders. Cybin employs a scientific approach to drug discovery and development, utilizing proprietary drug delivery systems and innovative compounds to create potentially safer and more effective treatments. Its pipeline includes several psychedelic-based molecules undergoing preclinical and clinical trials, with a strong emphasis on intellectual property protection and strategic partnerships to advance its research. The company aims to transform mental healthcare through the responsible and evidence-based application of psychedelic medicine.